• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

Anastrazole superior to tamoxifen for breast cancer treatment [Classics Series]

byLeah Hawkins Bressler, MD, MPH
August 9, 2018
in General Medicine Classics, Obstetrics, Obstetrics and Gynecology Classics, Oncology, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Postmenopausal women with advanced breast cancer randomized to anastrazole as first-line therapy experienced an increase in time to progression and a more favorable side effect profile compared to women randomized to tamoxifen treatment.

Original Date of Publication: November 2000

Study Rundown: Postmenopausal breast cancer is classically a hormone-responsive disease whereby the majority of tumors require estrogen stimulation to grow. Tamoxifen is a selective estrogen receptor modulator (SERM) that antagonizes estrogen receptors in the breast and uterus and acts as an agonist, or activator, of estrogen receptors in bone. In the treatment of postmenopausal breast cancer, chemotherapy and endocrine treatment in the form of tamoxifen therapy has been shown to be beneficial. While tamoxifen has been demonstrated to prolong survival and reduce incidence of contralateral breast tumors, its use is also associated with a 2-3 fold increased risk of developing endometrial cancer. Further, while tamoxifen is an estrogen receptor antagonist in the breast, it can also act as a partial agonist such that it may not maximally suppress the effects of estrogen. In the late 1990s, researchers hypothesized that aromatase inhibitors, which inhibit aromatase and thus block the conversion of androgens to estrogens in the peripheral adipose, might allow for more complete estrogen suppression. Anastrazole (also known as arimidex) is an aromatase inhibitor that demonstrated promise in prolonging survival in women with advanced stage breast cancer. In the present work, researchers conducted a large international randomized trial to compare the efficacy and tolerability of anastrazole and tamoxifen among women with advanced postmenopausal breast cancer.

Results of the present work represent the North American arm of the TARGET trial (Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study), a large international study comparing the efficacy and tolerability of these 2 drugs as first-line treatment of advanced breast cancer in 668 postmenopausal women. Findings demonstrated that anastrazole was at least as effective as tamoxifen as first-line therapy for postmenopausal breast cancer and was associated with a significantly increased time to progression and greater clinical benefit. Further, fewer incidents of thromboembolic events and postmenopausal vaginal bleeding were observed in women on anastrazole. Investigation of the efficacy and tolerability of anastrazole for premenopausal breast cancer and for primary chemoprophylaxis in women at high risk for breast cancer (e.g. BRCA carriers, women with ductal carcinoma in situ) is merited.

Click to study in the Journal of Clinical Oncology

In-Depth [randomized controlled trial]: A total of 353 postmenopausal women with advanced breast cancer were randomized across 97 study sites in the United States and Canada to daily treatment with anastrazole 1mg (n=171) or tamoxifen 20mg (n=182) as first-line therapy. Primary outcomes included objective response (OR), time to progression (TTP) and tolerability. Time to treatment failure (TTF), response duration and duration of benefit were also assessed.

Women randomized to anastrazole experienced a longer TTP interval compared to women on tamoxifen (11.1 vs. 5.6 months, respectively, p = 0.005), translating to a tamoxifen:anastrazole hazard ratio of 1.44. The proportion of women with demonstrable clinical benefit was higher in the anastrazole compared to tamoxifen group (59 vs. 46%, p < 0.01). Rates of thromboembolic events and vaginal bleeding were higher in women on tamoxifen.

RELATED REPORTS

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

Several factors influence health programs conducted in the African American Church

#VisualAbstract: Aromatase inhibitors significantly reduce recurrence in premenopausal women with ER+ breast cancer and ovarian suppression

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: anastrazoleBreast Cancertamoxifen
Previous Post

Women internists earn less than men whether they are generalists, hospitalists, or sub-specialists

Next Post

Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity

RelatedReports

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
StudyGraphics

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

May 18, 2022
Wellness

Several factors influence health programs conducted in the African American Church

May 18, 2022
#VisualAbstract: Aromatase inhibitors significantly reduce recurrence in  premenopausal women with ER+ breast cancer and ovarian suppression
StudyGraphics

#VisualAbstract: Aromatase inhibitors significantly reduce recurrence in premenopausal women with ER+ breast cancer and ovarian suppression

May 3, 2022
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Oncology

Comparison of mastectomy and breast reconstruction versus conservative surgery with radiation

April 26, 2022
Next Post
Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity

Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity

Bariatric surgery linked to significant reduction in microvascular complications of type 2 diabetes

Nonmedical expenses of pediatric hospitalizations have disproportionate effects

Nonmedical expenses of pediatric hospitalizations have disproportionate effects

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind May 22nd, 2022
  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.